Brief: Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual Meeting
02/06/2026 14:12
BRIEF-Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual Meeting June 2 (Reuters) - Cardiff Oncology Inc CRDF.O:
CARDIFF ONCOLOGY ANNOUNCES PRESENTATION OF POSITIVE RESULTS FROM ITS RANDOMIZED, CONTROLLED PHASE 2 TRIAL OF ONVANSERTIB IN FIRST-LINE RAS-MUTATED MCRC AT THE 2026 ASCO ANNUAL MEETING
CARDIFF ONCOLOGY - PHASE 2 TRIAL ACHIEVES PRIMARY GOAL SELECTING ONVANSERTIB DOSE FOR REGISTRATION
CARDIFF ONCOLOGY - MEDIAN PFS NOT REACHED IN ONVANSERTIB PLUS FOLFIRI/BEVACIZUMAB ARMS
CARDIFF ONCOLOGY - ONVANSERTIB SAFE AND WELL-TOLERATED WITH NO NEW TOXICITIES ADDED TO SOC
CARDIFF ONCOLOGY - 30 MG ONVANSERTIB PLUS FOLFIRI/BEVACIZUMAB ARM SHOWS ORR OF 72.2% VERSUS 42.1% FOR SOC
Source text: ID:nGNX9Zw6Kr
Further company coverage: CRDF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiff Oncology
See all newsBrief: Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia
Corrected: Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Cardiff Oncology sinks on direct equity offering